Meghan McCormick1, Erika Friehling1, Ramasubramanian Kalpatthi1, Nalyn Siripong2, Kenneth Smith3. 1. Division of Pediatric Hematology-Oncology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania. 2. The Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Infections are the leading cause of therapy-related mortality in pediatric patients with acute myeloid leukemia (AML). Although effectiveness of levofloxacin antibacterial prophylaxis in oncology patients is recognized, its cost-effectiveness is unknown. This study evaluated epidemiologic data regarding levofloxacin use and the cost-effectiveness of this strategy as the cost per bacteremia episode, intensive care unit (ICU) admission, and death avoided in children with AML. PROCEDURE: A retrospective cohort study using the Pediatric Health Information System (PHIS) database compared demographic and clinical characteristics and receipt of levofloxacin prophylaxis in children with AML admitted for chemotherapy from January 1, 2014, through December 31, 2018. We then developed a decision analysis model in this population that compared costs associated with bacteremia, ICU admission, or death secondary to bacteremia to levofloxacin prophylaxis cost from a healthcare perspective. Time horizon is one chemotherapy cycle. Probabilistic and one-way sensitivity analyses evaluated model uncertainty. RESULTS: Prophylaxis cost $8491 per bacteremia episode prevented compared with an average added hospital cost of $119 478. Prophylaxis cost $81 609 per ICU admission avoided, compared with an average added hospital cost of $94 181. Prophylaxis cost $220 457 per death avoided. In sensitivity analysis, at a willingness-to-pay threshold of $100 000 per bacteremia episode avoided, prophylaxis remained cost-effective in 94.6% of simulations. Prophylaxis use was more common in recent years in patients with relapsed disease and with chemotherapy regimens considered more intensive. CONCLUSION: Prophylaxis is cost-effective in preventing bacterial infections in patients with AML. Findings support increased use in patients considered at high risk of bacterial infection secondary to myelosuppression.
BACKGROUND:Infections are the leading cause of therapy-related mortality in pediatric patients with acute myeloid leukemia (AML). Although effectiveness of levofloxacin antibacterial prophylaxis in oncology patients is recognized, its cost-effectiveness is unknown. This study evaluated epidemiologic data regarding levofloxacin use and the cost-effectiveness of this strategy as the cost per bacteremia episode, intensive care unit (ICU) admission, and death avoided in children with AML. PROCEDURE: A retrospective cohort study using the Pediatric Health Information System (PHIS) database compared demographic and clinical characteristics and receipt of levofloxacin prophylaxis in children with AML admitted for chemotherapy from January 1, 2014, through December 31, 2018. We then developed a decision analysis model in this population that compared costs associated with bacteremia, ICU admission, or death secondary to bacteremia to levofloxacin prophylaxis cost from a healthcare perspective. Time horizon is one chemotherapy cycle. Probabilistic and one-way sensitivity analyses evaluated model uncertainty. RESULTS: Prophylaxis cost $8491 per bacteremia episode prevented compared with an average added hospital cost of $119 478. Prophylaxis cost $81 609 per ICU admission avoided, compared with an average added hospital cost of $94 181. Prophylaxis cost $220 457 per death avoided. In sensitivity analysis, at a willingness-to-pay threshold of $100 000 per bacteremia episode avoided, prophylaxis remained cost-effective in 94.6% of simulations. Prophylaxis use was more common in recent years in patients with relapsed disease and with chemotherapy regimens considered more intensive. CONCLUSION: Prophylaxis is cost-effective in preventing bacterial infections in patients with AML. Findings support increased use in patients considered at high risk of bacterial infection secondary to myelosuppression.
Authors: Ron Ben Abraham; Amos Toren; Nava Ono; Avi A Weinbroum; Amir Vardi; Zohar Barzilay; Gideon Paret Journal: J Pediatr Hematol Oncol Date: 2002-01 Impact factor: 1.289
Authors: Tamara P Miller; Kelly D Getz; Marko Kavcic; Yimei Li; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Marla Daves; Terzah M Horton; Michael A Pulsipher; Jessica Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Alan S Gamis; Richard Aplenc Journal: Leuk Lymphoma Date: 2016-01-04
Authors: Uma H Athale; Maneka Puligandla; Kristen E Stevenson; Barbara Asselin; Luis A Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Maria Luisa Sulis; Jennifer J G Welch; Marian H Harris; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman Journal: Pediatr Blood Cancer Date: 2018-06-07 Impact factor: 3.167
Authors: Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo Journal: Blood Date: 2007-11-13 Impact factor: 22.113
Authors: Ashley E J Rogers; Kristen M Eisenman; Susan A Dolan; Kristin M Belderson; Jocelyn R Zauche; Suhong Tong; Jane Gralla; Joanne M Hilden; Michael Wang; Kelly W Maloney; Samuel R Dominguez Journal: Pediatr Blood Cancer Date: 2016-09-12 Impact factor: 3.167
Authors: Thomas Lehrnbecher; Brian T Fisher; Bob Phillips; Sarah Alexander; Roland A Ammann; Melissa Beauchemin; Fabianne Carlesse; Elio Castagnola; Bonnie L Davis; L Lee Dupuis; Grace Egan; Andreas H Groll; Gabrielle M Haeusler; Maria Santolaya; William J Steinbach; Marianne van de Wetering; Joshua Wolf; Sandra Cabral; Paula D Robinson; Lillian Sung Journal: Clin Infect Dis Date: 2020-06-24 Impact factor: 9.079